Significantly more EUFLEXXA patients were pain free2*

PERCENTAGE WHO WERE PAIN FREE

PERCENTAGE WHO WERE PAIN FREE


EUFLEXXA: 63% vs Synvisc: 52% (P=0.038)

An additional 1 out of every 5 patients was pain free†*
with EUFLEXXA compared to Synvisc (101/160 vs 84/161, respectively; P=0.038)

Percentage of patients with an average score of ≤20 mm for the 5 WOMAC pain questions at Week 12 Synvisc (n=161) and EUFLEXXA (n=160)

Synvisc=hylan G-F 20.
WOMAC=Western Ontario and McMaster University Osteoarthritis Index.
*Pain free is defined as symptom free for the 5 WOMAC pain questions (with average VAS scores of <20 mm) measured at Week 12.
Of the patients in the trial who became pain free, there were 17 (20%) more in the EUFLEXXA group than in the Synvisc group.

Please See Important Safety Information and Full Prescribing Information.

INDICATION

EUFLEXXA® [1% sodium hyaluronate] is indicated for the treatment of pain in osteoarthritis [DA] of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics [eg, acetaminophen].

IMPORTANT SAFETY INFORMATION

EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.

EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.

Do not inject intravascularly due to potential for systemic adverse events.

The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.

The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.

Please see Full Prescribing Information.

Please see Full Prescribing Information.